Amgen Oncology’s Post

IV medicines Can Be Turned into Pills Without Losing Effectiveness Injectables are widely used in medical practice, but for most patients, this is an inconvenient or unavailable option because it requires regular hospital visits. For example, cancer patients spend many hours in hospitals to receive chemotherapy through an IV. Scientists at Stanford have solved this problem in an elegant way - they have developed a special chemical tag that first marks the drug as water-soluble, and then as fat-soluble. Initial experiments have shown that this technology dramatically increases the bioavailability and effectiveness of drugs. https://lnkd.in/ezXju4EB

🎄 Episode 121: Christmas Special 🎄 "Curenetics - Can we use AI to Predict Response to Checkpoint Inhibitor Immunotherapy?" In this special festive episode, hosts Dr Ricky Frazer and Dr Anna Olsson-Brown-brown sit down with Dr. Sola Adeleke, Founder and CMO of Curenetics, along with some of the team behind this innovative approach. Learn how AI is shaping the future of immunotherapy by predicting patient responses to checkpoint inhibitors. 👇 Let us know what you think in the comments below. 🎧 Tune in now! #AI #Biotech #Pharma #Innovation #AIinHealthcare #MachineLearning #Immunotherapy

[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on phase II/III SKYSCRAPER-06 study in metastatic non-squamous non-small cell lung cancer SKYSCRAPER-06 evaluating tiragolumab plus Tecentriq and chemotherapy did not meet the primary endpoints of progression-free survival at primary analysis and overall survival at first interim analysisThe combination of tiragolumab plus Tecentriq and ... https://lnkd.in/em8RUFxf #BioTech #science

When you’re under pressure to make critical decisions, you need a system innovated to rise to the challenge. Whether you're progressing high potency drug candidates into clinical trials, staying prepared for changing #PFAS regulations, or investing years in researching a biomarker that could later be used to help develop a diagnostic cancer test in a diagnostic application, the decisions you make count. 𝗙𝗲𝗮𝘁𝘂𝗿𝗶𝗻𝗴 1. Mass Guard Technology 2. Removable DJet+ assembly 3. Speeds of up to 800 MRM per second Find out more about the high sensitivity, speed and resilience offered by our new 𝗦𝗖𝗜𝗘𝗫 𝟳𝟱𝟬𝟬+ 𝘀𝘆𝘀𝘁𝗲𝗺 across large, complex sample sets. Visit our new product page to learn more 👉 https://bit.ly/3R8A5GF 𝗦𝗖𝗜𝗘𝗫. 𝗪𝗵𝗲𝗻 𝗶𝘁 𝗰𝗼𝘂𝗻𝘁𝘀. #SCIEX7500Plus #ASMS2024 #SCIEXforScience #FutureOfMassSpec #Innovation #MassSpectrometry

🔥 𝙍𝙖𝙙𝙞𝙤𝙩𝙝𝙚𝙧𝙖𝙥𝙮 𝙖𝙣𝙙 𝙩𝙝𝙚𝙧𝙖𝙣𝙤𝙨𝙩𝙞𝙘𝙨: 𝙖 𝙇𝙖𝙣𝙘𝙚𝙩 𝙊𝙣𝙘𝙤𝙡𝙤𝙜𝙮 𝘾𝙤𝙢𝙢𝙞𝙨𝙨𝙞𝙤𝙣 , an important document just published that needs to be part of the conversation when considering investing in and promoting #radiotheranostics. The document discusses global disparities in access to #radiotherapy and #theranostics, highlighting disparities between high-income countries and low- and middle-income #countries, and the challenges they faced such as lack of equipment, trained professionals, and treatment access, among other. The report also identifies obstacles in the availability of #radiopharmaceutical therapies due to supply chain and regulatory issues. The Commission calls for 𝗴𝗹𝗼𝗯𝗮𝗹 𝗲𝗳𝗳𝗼𝗿𝘁𝘀 to address investment in 𝗶𝗻𝗳𝗿𝗮𝘀𝘁𝗿𝘂𝗰𝘁𝘂𝗿𝗲, 𝘁𝗿𝗮𝗶𝗻𝗶𝗻𝗴, and 𝗽𝗼𝗹𝗶𝗰𝘆 𝗶𝗻𝗶𝘁𝗶𝗮𝘁𝗶𝘃𝗲𝘀 to bridge these gaps and ensure more equitable a𝗮𝗰𝗰𝗲𝘀𝘀 𝘁𝗼 #𝗰𝗮𝗻𝗰𝗲𝗿 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁𝘀 𝗴𝗹𝗼𝗯𝗮𝗹𝗹𝘆. 👇

𝙍𝙖𝙙𝙞𝙤𝙩𝙝𝙚𝙧𝙖𝙥𝙮 𝙖𝙣𝙙 𝙩𝙝𝙚𝙧𝙖𝙣𝙤𝙨𝙩𝙞𝙘𝙨: 𝙖 𝙇𝙖𝙣𝙘𝙚𝙩 𝙊𝙣𝙘𝙤𝙡𝙤𝙜𝙮 𝘾𝙤𝙢𝙢𝙞𝙨𝙨𝙞𝙤𝙣 , an important document recently published that needs to be part of the conversation when considering investing in and promoting radio-pharmaceuticals and theranostics. #radiotheranostics #RLT #CancerCare

Interested in learning more about Ori Biotech's new #IRO manufacturing platform? More detail and data showcasing our ability to automate better biology in the release below. #CGT #CellTherapy #Biotechnology

Questions about current and future roles of #MRD testing abound, including validation of assays, standardization of collection methods, clinical trial considerations, and roles of MRD status and depth of response across #hematologic #malignancies. Learn more about how these questions are being answered in this activity: https://bit.ly/49v2Vbq #MRDTesting #CancerResearch #OncologyInsights #MedicalAdvancements #ClinicalTrialConsiderations

The demand for innovation in cancer care has never been greater, especially with an anticipated doubling of cancer cases in Sweden over the next 15 years. At BMS, we firmly believe that innovation should be diverse, inclusive and impactful throughout the patient journey. By bringing treatment closer to patients, hospitals can prioritize emergency care and research, benefiting patients, caregivers, healthcare professionals, and society at large. In the video below, I share some perspectives on the need to collaborate with many actors in the healthcare ecosystem and develop new solutions that benefit all Swedish patients. #BMSEmployee #gränbyprojektet #tillgängligcancervård #akademiskasjukhuset